Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye.

Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.